References
- Schuetz J D, Westin E H, Matherly L H. Membrane protein changes in an L1 210 leukemia cell line with a translocation defect in the methotrexate-tetrahydrofolate cofactor transport carrier. J Biol Chem 1989; 264: 16261–16267
- Bemal S D, Speak J A, Boeheim K. Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum. Mol Cell Biocbem 1990; 95: 61–70
- Frei E, Rosowsky A, Wright J E. Development of methotrexate resistance in a human squamous cell carcinoma of the head and neck in culture. Proc Natl Acad Sci USA 1984; 81: 2873–2877
- Rosowsky A, Wright J E, Cucchi C A. Phenotypic heterogeneity in cultured human head and neck squamous cell carcinoma lines with low-level methotrexate resistance. Cancer Res 1985; 45: 6205–6212
- Ohnuma T, Lo R J, Scanlon K J. Evolution of methotrexate resistance of human acute lymphohlastic leukemia cells in vitro. Cancer Res 1985; 45: 1815–1822
- Assaraf Y G, Schimke R T. Identification of MTX transport deficiency in mammalian cells using fluoresceinated MTX and flow cytometry. Proc Natl Acad Sci USA 1987; 84: 7154–7158
- Schuetz J D, Matherly L H, Westin E H. Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate-resistant murine L1210 leukemia cell line. J Biol Chem 1988; 263: 9840–9847
- Rheinwald J B, Beckett M A. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res 1981; 41: 1657–1663
- Boheim K, Speak J A, Frei E, III. SQMl antibody defines a surface membrane antigen in squamous carcinoma of the head and neck. Int J Cancer 1985; 36: 137–142
- Stahel R A, Speak J A, Bemal S D. Murine monoclonal antibody LAM2 defines cell membrane determinant with preferential expression on human lung small-cell carcinoma and squamous-cell carcinomas. Int J Cancer 1985; 35: ll–17
- Bernal S D, Cualing H M, Stahel R A. Immunology of lung cancer. Immunology of Lung Cancer: Diagnosis and Treatment, PG Abrams, ST Rosen. Marcel Dekker, New York 1988; 213–236
- Kamen B A, Takach P L, Vatev R. A rapid radiochemical ligand binding assay for methotrexate. Anal Biochem 1976; 70: 54–63
- Jolivet G, Schilsky R L, Bailey B D. Synthesis, retention and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest 1982; 70: 351–360
- Goldman I D, Lichtenstein NS, Oliverio V T. Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem 1968; 243: 5007–5017
- Sirotnak F M, Moccio D M, Yang C-H. A novel class of genetic variants of the L1210 cell up-regulated for folate analogue transport inward. J Biol Chem 1984; 259: 13139–13144
- Lowry O H, Rosebrough N J, Farr A L. Protein measurements with the folin phenol reagent. J Biol Chem 1951; 193: 265–275
- Goldman I D. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann NY Acad Sci 1971; 186: 400–422
- Fry D W, White J C, Goldman I D. Alterations of the carrier-mediated transport of an anionic solute MTX, by charged liposomes in Ehrlich ascites tumor cells. J Memhr Biol 1979; 50: 123–140
- Fry D W, Goldman I D. Further studies on the charge-related alterations of MTX transport in Ehrlich ascites tumor cells by ionic liposomes: correlation with liposome-cell association. J Membr Biol 1982; 66: 97–95
- Sirotnak F M, Poser R E, Barmeco J R. Enhancement of folate analogue transport inward in L12110 cells during MTX therapy of leukemic mice: Evidence of the nature of the effect, possible host mediation, and pharmacokinetic significance. Cancer Res 1987; 47: 5334–5339
- Freisheim J H, Ratnam M, McAlinden T P. Molecular events in the membrane transport of methotrexate in human CCRF-CEM leukemia cell lines. Adv Enzyme Regul 1992; 32: 17–31